Theriva Biologics
TOVX
24 hedge funds and large institutions have $1.15M invested in Theriva Biologics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 9 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0.26% more ownership
Funds ownership: 0.03% → 0.29% (+0.26%)
20% less funds holding
Funds holding: 30 → 24 (-6)
54% less capital invested
Capital invested by funds: $2.52M → $1.15M (-$1.37M)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$86.1K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$43.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19.2K |
| 4 |
VF
Virtu Financial
New York
|
+$19.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$17.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
-$256K |
| 2 |
Two Sigma Investments
New York
|
-$34K |
| 3 |
MP
MSD Partners
New York
|
-$25K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.02K |
| 5 |
LFA
Landmark Financial Advisors
Bowling Green,
Kentucky
|
-$5K |
TOVX Hedge Fund Activity: Q3 2022 in Review
24 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2022, worth a combined $1.15M — down 54% from $2.52M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TOVX and 3 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $86.1K. The largest seller was Truist Financial, exiting entirely with an estimated $256K sold.
- 24 institutional investors held Theriva Biologics (TOVX) as of Q3 2022, down from 30 in Q2 2022.
- Funds reported $1.15M of Theriva Biologics stock for Q3 2022, down 54% quarter-over-quarter.
- 3 funds opened new Theriva Biologics positions in Q3 2022 and 9 closed out, a net change of -6 holders.
- The largest Theriva Biologics buyer in Q3 2022 was Citadel Advisors, an estimated $86.1K added.
- The largest Theriva Biologics seller in Q3 2022 was Truist Financial, an estimated $256K sold.
Based on aggregated 13F filings for Q3 2022.